Isidora Panez-Toro, Javier Muñoz-García, Jorge W Vargas-Franco, Axelle Renodon-Cornière, Marie-Françoise Heymann, Frédéric Lézot, Dominique Heymann
PURPOSE OF REVIEW: This article gives a brief overview of the most recent developments in osteosarcoma treatment, including targeting of signaling pathways, immune checkpoint inhibitors, drug delivery strategies as single or combined approaches, and the identification of new therapeutic targets to face this highly heterogeneous disease. RECENT FINDINGS: Osteosarcoma is one of the most common primary malignant bone tumors in children and young adults, with a high risk of bone and lung metastases and a 5-year survival rate around 70% in the absence of metastases and 30% if metastases are detected at the time of diagnosis...
June 17, 2023: Current Osteoporosis Reports